Chimerix CEO M. Michelle Berrey to stand down as interim Office of Cheif Executive Officer is formed
The North Carolina-based biopharmaceutical company Chimerex has announced that Dr M. Michelle Berrey has resigned from her role as President and CEO.
In her place Dr W. Garrett Nichols, Timothy W. Trost and Michael A. Alrutz have been appointed to the newly created Office of the Chief Executive Officer on an interim basis until a replacement is found.
In addition to their roles in the Office of the Chief Executive Officer, Dr Nichols will continue to serve as Chief Medical Officer, Trost will continue to serve as Chimerix’s Senior Vice President, Chief Financial Officer and Corporate Secretary; and Alrutz will continue to serve as Chimerix’s Senior Vice President, General Counsel.
“We would like to express our sincere appreciation for Michelle’s more than six years of service to Chimerix, as both Chief Executive Officer and formerly Chief Medical Officer. Thanks to Michelle’s leadership, we have advanced the understanding of dangerous viral infections that impact patients after stem cell transplant and have significantly progressed our clinical development program for brincidofovir. We wish her well in her future endeavors,” said Martha J. Demski, Chair of the Chimerix Board of Directors.
“As Chimerix looks ahead, we are pleased to have such experienced and knowledgeable executives as Garrett, Tim and Michael to take on expanded leadership roles in shepherding the Company’s ongoing clinical trials for oral, short-course and intravenous brincidofovir and developing oral brincidofovir as a medical countermeasure for smallpox.”
Shares in Chimerix were down on announcement of the news. The news comes after shares in the firm plummeted by as much as 79.7 percent, in reaction to the failure of its antiviral drug brincidofovir, in December 2015.